Alpha 2.0
Login Register
» Authors » Simonetta Mocci

Simonetta Mocci

Explore the profile of Simonetta Mocci including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 1508
Followers 0
Related Specialties
Oncology
General Medicine
Science
Top 10 Co-Authors
Alan Sandler
Enriqueta Felip
Marcin Kowanetz
David S Shames
David R Spigel
Tony Mok
Solange Peters
Dustin Smith
Wei Zou
Priti S Hegde
Published In
J Clin Oncol
PLoS One
J Thorac Oncol
J Rheumatol
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer
Tolaney S, DeMichele A, Takano T, Rugo H, Perou C, Lynce F, et al.
Future Oncol . 2024 Jun; 20(31):2343-2355. PMID: 38922307
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoadjuvant therapy have a high risk of recurrence even with neoadjuvant and adjuvant treatment with pembrolizumab. Sacituzumab govitecan,...
2.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel S, Cheema P, et al.
Nat Med . 2022 Aug; 28(9):1831-1839. PMID: 35995953
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy...
3.
Concordance Between Tissue Detection by Immunohistochemistry and Plasma Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced -Positive NSCLC
Noe J, Bordogna W, Archer V, Smoljanovic V, Hilton M, Woodhouse R, et al.
JTO Clin Res Rep . 2022 Jun; 3(7):100341. PMID: 35756755
Introduction: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with -positive NSCLC for alectinib treatment. To understand the relationship between tissue-based...
4.
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Dziadziuszko R, Mok T, Peters S, Han J, Alatorre-Alexander J, Leighl N, et al.
J Thorac Oncol . 2021 Jul; 16(12):2040-2050. PMID: 34311110
Introduction: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of...
5.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC
Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios C, Morise M, et al.
J Thorac Oncol . 2021 Jul; 16(11):1872-1882. PMID: 34265434
Introduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1...
6.
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
Patil N, Zou W, Mocci S, Sandler A, Ballinger M, Flynn S, et al.
PLoS One . 2021 Feb; 16(2):e0246486. PMID: 33534859
Purpose: Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung...
7.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C, et al.
N Engl J Med . 2020 Sep; 383(14):1328-1339. PMID: 32997907
Background: The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell...
8.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Kowanetz M, Zou W, Gettinger S, Koeppen H, Kockx M, Schmid P, et al.
Proc Natl Acad Sci U S A . 2018 Oct; 115(43):E10119-E10126. PMID: 30297397
Programmed death-ligand 1 (PD-L1) expression on tumor cells (TCs) by immunohistochemistry is rapidly gaining importance as a diagnostic for the selection or stratification of patients with non-small cell lung cancer...
9.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey J, et al.
Appl Immunohistochem Mol Morphol . 2018 Jan; 27(2):92-100. PMID: 29346180
Cancer immunotherapies, such as atezolizumab, are proving to be a valuable therapeutic strategy across indications, including non-small cell lung cancer (NSCLC) and urothelial cancer (UC). Here, we describe a diagnostic...
10.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, Gettinger S, Johnson M, Janne P, Garassino M, Christoph D, et al.
J Clin Oncol . 2017 Jun; 35(24):2781-2789. PMID: 28609226
Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non-small-cell lung cancer (NSCLC) across lines of therapy. Patients were...